Sihuan Pharmaceutical Holdings Group Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2010-10-28. The firm operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
Sihuan Pharmaceutical Holdings Group Ltd의 CEO는 누구입니까?
Dr. Weicheng Guo은 2006부터 회사에 합류한 Sihuan Pharmaceutical Holdings Group Ltd의 Executive Deputy Chairman of the Board입니다.
SHPHY 주식의 가격 성능은 어떻습니까?
SHPHY의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Sihuan Pharmaceutical Holdings Group Ltd의 주요 사업 주제나 업종은 무엇입니까?
Sihuan Pharmaceutical Holdings Group Ltd은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Sihuan Pharmaceutical Holdings Group Ltd의 시가총액은 얼마입니까?
Sihuan Pharmaceutical Holdings Group Ltd의 현재 시가총액은 $0입니다
Sihuan Pharmaceutical Holdings Group Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Sihuan Pharmaceutical Holdings Group Ltd에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 2명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
